CDSCO flags 59 sampled of drugs as “not of standard quality”
CDSCO flagged 59 drug samples as “not of standard quality” in October 2023, out of the 1,105 samples that were tested.
The Central Drugs Standard Control Organisation (CDSCO) flagged 59 drug samples, including those from reputed companies, as “not of standard quality.” This was announced back in October 2023. Now in a recent alert, the CDSCO revealed that out of 1,105 samples tested, 61 were found to be substandard.
Among the flagged samples were two unlabelled vials purported to contain Tigecycline 50 mg and two samples of phenolic disinfecting multipurpose surface cleaner-cum-deodoriser (Lytner). The CDSCO clarified that the count comes to 59 drugs “not of standard quality” as samples of two drugs were repeated in the testing process.
The drug samples underwent testing at various statutory laboratories authorized by the CDSCO. Some of the other drugs that are marked as “not of standard quality” include the following:
Cefixime Oral Suspension IP, Amoxycilin, Potassium Clavulanate, and Lactic Acid Bacillus Tablets (GAMPCLAV-625 LB Tablets), Rabeprazole Sodium (Enteric Coated) and Domperidone (Sustained Release) capsules. Further, the list also includes Diclofenac Sodium Tablets IP 50 mg, Albendazole Tablets I.P. 400 mg, Ofloxacin, Ornidazole, Itraconazole, and Clobetasol Propionate Cream (Derma -RX Cream), and Vitamin C (Orange Syrup).
This alert from the CDSCO has raised concerns about the quality of certain drugs in the market, emphasizing the need for stringent monitoring and adherence to quality standards in order to ensure the safety of pharmaceutical products.
Ms Kalinga